[2014-Dec-19] FDA approves new antibacterial drug Zerbaxa

[2014-Dec-19] FDA approves new antibacterial drug Zerbaxa

http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm427534.htm

Zerbaxa.cdx

Shinobu Takeda, Toru Nakai, Yoshimi Wakai, Fumiaki Ikeda and Kazuo Hatano, In Vitro and In Vivo Activitiesof a New Cephalosporin, FR264205, against Pseudomonas aeruginosa, Antimicrob. Agents Chemother., 2007, 51 (3), pp 826-830

http://dx.doi.org/10.1128/AAC.00860-06

David J. Payne, Rebecca Cramp, David J. Winstanley and David J. C. Knowles, Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases. Antimicrob. Agents Chemother., 1994, 38 (4), pp 767-772

http://dx.doi.org/10.1128/AAC.38.4.767

Efthimios E. Prinarakis, Vivi Miriagou, Eva Tzelepi, Maria Gazouli and Leonidas S. Tzouvelekis, Emergence of an inhibitor-resistant beta-lactamase (SHV-10) derived from an SHV-5 variant, Antimicrob. Agents Chemother., 1997, 41 (4), pp 838-840

http://aac.asm.org/content/41/4/838.abstract

H. Bermudes, F. Jude, E. B. Chaibi, C. Arpin, C. Bebear, R. Labia, and C. Quentin, Molecular Characterization of TEM-59 (IRT-17), a Novel Inhibitor-Resistant TEM-Derived β-Lactamase in a Clinical Isolate of Klebsiella oxytoca, Antimicrob. Agents Chemother., 1999, 43 (7), pp 1657-1661

http://aac.asm.org/content/43/7/1657.abstract

E. B. Chaïbi, D. Sirot, G. Paul and R. Labia, Inhibitor-resistant TEM β-lactamases: phenotypic, genetic and biochemical characteristics, J. Antimicrob. Chemother., 1999, 43 (4), pp 447-458

http://dx.doi.org/10.1093/jac/43.4.447

Youjun Yang, Beth A Rasmussen, David M Shlaes, Class A β-lactamases—enzyme-inhibitor interactions and resistance, Pharmacol. Ther., 1999, 83 (2), pp 141-151

http://dx.doi.org/10.1016/S0163-7258(99)00027-3